Semnur Pharmaceuticals Signs $100 Million Investment Agreement with iHolding
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: Globenewswire
- Investment Agreement Signed: Semnur Pharmaceuticals has signed a $100 million investment agreement with iHolding Group LLP, which plans to purchase 10 million newly issued shares at $10 each, providing crucial funding for the company's product development and commercialization activities.
- Clinical Program Advancement: The investment will support the ongoing Phase 3 clinical program for SEMDEXA™ (SP-102), aimed at providing non-opioid pain relief for patients with moderate to severe chronic radicular pain, addressing a significant unmet medical need in the market.
- Strategic Partnership Potential: iHolding's investment not only highlights Kazakhstan's growing role in global biopharmaceutical innovation but also aligns with its long-term strategy to establish Kazakhstan as a regional hub for pharmaceutical manufacturing and R&D, enhancing global supply chain relationships.
- Future Growth Outlook: Semnur's CEO emphasized that this investment will drive the company's strategic growth, enhance its competitiveness in international markets, and lay the groundwork for future product development and market expansion.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SCLX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SCLX
About SCLX
Scilex Holding Company is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company’s commercial products include ZTlidoO (lidocaine topical system) 1.8% for the relief of neuropathic pain associated with postherpetic neuralgia (PHN); ELYXYB, a ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, it focuses on product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXAO), an epidural injections formulation to treat lumbosacral radicular pain, or sciatica; SP-103 (lidocaine topical system) 5.4%, a ZTlido formulation, for the treatment of acute pain; and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (SP-104) for fibromyalgia treatment.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Semnur Pharmaceuticals Signs $100 Million Investment Agreement with iHolding
- Investment Agreement Signed: Semnur Pharmaceuticals has signed a $100 million investment agreement with iHolding Group LLP, which plans to purchase 10 million newly issued shares at $10 each, providing crucial funding for the company's product development and commercialization activities.
- Clinical Program Advancement: The investment will support the ongoing Phase 3 clinical program for SEMDEXA™ (SP-102), aimed at providing non-opioid pain relief for patients with moderate to severe chronic radicular pain, addressing a significant unmet medical need in the market.
- Strategic Partnership Potential: iHolding's investment not only highlights Kazakhstan's growing role in global biopharmaceutical innovation but also aligns with its long-term strategy to establish Kazakhstan as a regional hub for pharmaceutical manufacturing and R&D, enhancing global supply chain relationships.
- Future Growth Outlook: Semnur's CEO emphasized that this investment will drive the company's strategic growth, enhance its competitiveness in international markets, and lay the groundwork for future product development and market expansion.
See More
Scilex Launches Dream Bowl Token Trading on Biconomy Exchange
- Token Trading Launch: Scilex commenced trading of Dream Bowl Tokens on July 6, 2026, on the Biconomy Exchange, aiming to provide liquidity and broaden distribution for shareholders, which is expected to enhance interaction between the company and its investors.
- Market Potential: The Biconomy Exchange serves over 10 million users with an average daily trading volume of approximately $2 billion, and as one of the top 40 global exchanges, its security and liquidity will strongly support the successful trading of Dream Bowl Tokens.
- Token Holdings: As of April 30, 2026, Scilex holds approximately 180 million Dream Bowl Tokens, ensuring the company's significant position in the token market and laying the groundwork for future capital operations.
- Strategic Development Direction: By launching the Dream Bowl Tokens, Scilex not only showcases its innovative capabilities in non-opioid pain management products but also indicates its commitment to leveraging blockchain technology to enhance market competitiveness and shareholder value.
See More
Scilex Secures $100 Million Investment from iHolding Group
- Significant Investment: Scilex Holding Company has signed a binding term sheet with iHolding Group, which plans to purchase 6,666,667 newly issued shares at $15 each, totaling $100 million, expected to provide robust financial support for Scilex's strategic growth.
- Support for Strategic Growth: The investment will be utilized to bolster Scilex's expansion in healthcare technology and product development, particularly focusing on non-opioid pain management solutions for acute and chronic pain, aiming to enhance the company's competitiveness in the rapidly evolving medical market.
- International Investment Potential: This investment by iHolding is regarded as one of the largest healthcare investments from Kazakhstan into a U.S.-listed biopharmaceutical company, highlighting the growing international interest in Scilex's differentiated commercial platform and pipeline, which may drive future market expansion.
- Long-term Partnership Vision: iHolding emphasizes that this investment is not merely a single transaction but a commitment to establishing strategic partnerships that accelerate innovation and position Kazakhstan as a regional hub for pharmaceuticals and biotechnology, enhancing global supply chain and industry connections.
See More
Oramed Pharmaceuticals Joins Russell Indexes, Strengthens Financial Position
- Russell Index Inclusion: Oramed Pharmaceuticals is set to be added to the Russell 2000 and Russell 3000 indexes on June 29, 2026, which is expected to enhance the company's visibility, broaden its shareholder base, and improve trading liquidity.
- Significant Loan Recovery: Oramed's investment in Scilex was approximately $99.5 million, and to date, it has recouped about $118 million, with an expected additional recovery of $43 million by October 2026, resulting in an overall return of 161%, showcasing strong capital recovery capabilities.
- Strong Financial Position: As of March 31, 2026, Oramed reported total cash and assets of approximately $270 million, providing a solid foundation for future investments and growth opportunities.
- Diversified Strategic Investments: Oramed has made significant investments in companies like Alpha Tau and Lifeward, with Alpha Tau's current valuation at approximately $167 million, highlighting its potential in the biomedical sector and further strengthening the company's investment portfolio.
See More
Biotech Companies See Significant Stock Gains
- Parabilis Debut Performance: Parabilis Medicines Inc. saw its stock surge 58% on its Nasdaq debut, pricing 33.5 million shares at $20 each, with expected gross proceeds of approximately $670 million, indicating strong market demand for its innovative drug candidates.
- Clover Health Legal Victory: Clover Health Investments Corp. achieved a legal victory against the U.S. Department of Health and Human Services, upgrading its PPO plan's star rating from 3.5 to 4.5, with projected total revenues for 2026 between $2.81 billion and $2.92 billion, reflecting a 49% year-over-year growth.
- Shoulder Innovations Growth: Shoulder Innovations, Inc. reported a net revenue of $16.7 million for Q1, a 65% increase year-over-year, and expects full-year 2026 revenues between $65 million and $68 million, representing a growth of 37% to 44%, showcasing its strong position in the shoulder surgical market.
- Myomo Stock Surge: Myomo Inc.'s stock rose over 17%, with projected Q2 2026 revenues between $10.3 million and $10.8 million, compared to $9.7 million in Q2 2025, reflecting increasing market demand for its wearable medical robotics products.
See More
Replimune Receives FDA Support for BLA Resubmission
- BLA Resubmission Progress: Replimune Group Inc. announced an agreement with the FDA to resubmit its Biologics License Application (BLA) for RP1 in advanced melanoma within days, which is expected to boost the company's stock price and enhance market confidence.
- Patent Filing Success: Clearmind Medicine Inc. successfully filed a patent in Japan for its 5-Methoxy-2-aminoindan (MEAI) aimed at treating depression, strengthening its global intellectual property portfolio and potentially laying the groundwork for future market expansion.
- Clinical Data Update: C4 Therapeutics Inc. is set to present updated clinical data on Cemsidomide on June 12, 2026, which is anticipated to positively impact its application in treating multiple myeloma, further increasing investor interest in the company.
- Optimistic Financial Outlook: Alpha Teknova Inc. reported total revenue of $11.1 million for Q1 2026, a 13% increase year-over-year, and expects full-year revenue to range between $42 million and $44 million, indicating strong growth potential in the bioreagent market.
See More
Semnur Pharmaceuticals Signs $100 Million Investment Agreement with iHolding
- Investment Agreement Signed: Semnur Pharmaceuticals has signed a $100 million investment agreement with iHolding Group LLP, which plans to purchase 10 million newly issued shares at $10 each, providing crucial funding for the company's product development and commercialization activities.
- Clinical Program Advancement: The investment will support the ongoing Phase 3 clinical program for SEMDEXA™ (SP-102), aimed at providing non-opioid pain relief for patients with moderate to severe chronic radicular pain, addressing a significant unmet medical need in the market.
- Strategic Partnership Potential: iHolding's investment not only highlights Kazakhstan's growing role in global biopharmaceutical innovation but also aligns with its long-term strategy to establish Kazakhstan as a regional hub for pharmaceutical manufacturing and R&D, enhancing global supply chain relationships.
- Future Growth Outlook: Semnur's CEO emphasized that this investment will drive the company's strategic growth, enhance its competitiveness in international markets, and lay the groundwork for future product development and market expansion.
See More
Scilex Launches Dream Bowl Token Trading on Biconomy Exchange
- Token Trading Launch: Scilex commenced trading of Dream Bowl Tokens on July 6, 2026, on the Biconomy Exchange, aiming to provide liquidity and broaden distribution for shareholders, which is expected to enhance interaction between the company and its investors.
- Market Potential: The Biconomy Exchange serves over 10 million users with an average daily trading volume of approximately $2 billion, and as one of the top 40 global exchanges, its security and liquidity will strongly support the successful trading of Dream Bowl Tokens.
- Token Holdings: As of April 30, 2026, Scilex holds approximately 180 million Dream Bowl Tokens, ensuring the company's significant position in the token market and laying the groundwork for future capital operations.
- Strategic Development Direction: By launching the Dream Bowl Tokens, Scilex not only showcases its innovative capabilities in non-opioid pain management products but also indicates its commitment to leveraging blockchain technology to enhance market competitiveness and shareholder value.
See More
Scilex Secures $100 Million Investment from iHolding Group
- Significant Investment: Scilex Holding Company has signed a binding term sheet with iHolding Group, which plans to purchase 6,666,667 newly issued shares at $15 each, totaling $100 million, expected to provide robust financial support for Scilex's strategic growth.
- Support for Strategic Growth: The investment will be utilized to bolster Scilex's expansion in healthcare technology and product development, particularly focusing on non-opioid pain management solutions for acute and chronic pain, aiming to enhance the company's competitiveness in the rapidly evolving medical market.
- International Investment Potential: This investment by iHolding is regarded as one of the largest healthcare investments from Kazakhstan into a U.S.-listed biopharmaceutical company, highlighting the growing international interest in Scilex's differentiated commercial platform and pipeline, which may drive future market expansion.
- Long-term Partnership Vision: iHolding emphasizes that this investment is not merely a single transaction but a commitment to establishing strategic partnerships that accelerate innovation and position Kazakhstan as a regional hub for pharmaceuticals and biotechnology, enhancing global supply chain and industry connections.
See More
Oramed Pharmaceuticals Joins Russell Indexes, Strengthens Financial Position
- Russell Index Inclusion: Oramed Pharmaceuticals is set to be added to the Russell 2000 and Russell 3000 indexes on June 29, 2026, which is expected to enhance the company's visibility, broaden its shareholder base, and improve trading liquidity.
- Significant Loan Recovery: Oramed's investment in Scilex was approximately $99.5 million, and to date, it has recouped about $118 million, with an expected additional recovery of $43 million by October 2026, resulting in an overall return of 161%, showcasing strong capital recovery capabilities.
- Strong Financial Position: As of March 31, 2026, Oramed reported total cash and assets of approximately $270 million, providing a solid foundation for future investments and growth opportunities.
- Diversified Strategic Investments: Oramed has made significant investments in companies like Alpha Tau and Lifeward, with Alpha Tau's current valuation at approximately $167 million, highlighting its potential in the biomedical sector and further strengthening the company's investment portfolio.
See More
Biotech Companies See Significant Stock Gains
- Parabilis Debut Performance: Parabilis Medicines Inc. saw its stock surge 58% on its Nasdaq debut, pricing 33.5 million shares at $20 each, with expected gross proceeds of approximately $670 million, indicating strong market demand for its innovative drug candidates.
- Clover Health Legal Victory: Clover Health Investments Corp. achieved a legal victory against the U.S. Department of Health and Human Services, upgrading its PPO plan's star rating from 3.5 to 4.5, with projected total revenues for 2026 between $2.81 billion and $2.92 billion, reflecting a 49% year-over-year growth.
- Shoulder Innovations Growth: Shoulder Innovations, Inc. reported a net revenue of $16.7 million for Q1, a 65% increase year-over-year, and expects full-year 2026 revenues between $65 million and $68 million, representing a growth of 37% to 44%, showcasing its strong position in the shoulder surgical market.
- Myomo Stock Surge: Myomo Inc.'s stock rose over 17%, with projected Q2 2026 revenues between $10.3 million and $10.8 million, compared to $9.7 million in Q2 2025, reflecting increasing market demand for its wearable medical robotics products.
See More
Replimune Receives FDA Support for BLA Resubmission
- BLA Resubmission Progress: Replimune Group Inc. announced an agreement with the FDA to resubmit its Biologics License Application (BLA) for RP1 in advanced melanoma within days, which is expected to boost the company's stock price and enhance market confidence.
- Patent Filing Success: Clearmind Medicine Inc. successfully filed a patent in Japan for its 5-Methoxy-2-aminoindan (MEAI) aimed at treating depression, strengthening its global intellectual property portfolio and potentially laying the groundwork for future market expansion.
- Clinical Data Update: C4 Therapeutics Inc. is set to present updated clinical data on Cemsidomide on June 12, 2026, which is anticipated to positively impact its application in treating multiple myeloma, further increasing investor interest in the company.
- Optimistic Financial Outlook: Alpha Teknova Inc. reported total revenue of $11.1 million for Q1 2026, a 13% increase year-over-year, and expects full-year revenue to range between $42 million and $44 million, indicating strong growth potential in the bioreagent market.
See More
